A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Breast Neoplasms
  • Paclitaxel

abstract

  • Paclitaxel given by 3-hour or 96-hour infusion was active in MBC. The 96-hour paclitaxel regimen did not significantly improve response or time to disease progression, was more cumbersome to administer, and was associated with greater myelosuppression (but less neuropathy and myalgia) compared with the 3-hour schedule.

publication date

  • February 15, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3806193

Digital Object Identifier (DOI)

  • 10.1002/cncr.24870

PubMed ID

  • 20052721

Additional Document Info

start page

  • 814

end page

  • 21

volume

  • 116

number

  • 4